Research & Development
CorMatrix Cardiovascular Inc passes US FDA 510(k) clearance for Cor PATCH epicardial patch for tissue support and repair in adult patients
12 June 2019 -

Cardiovascular company CorMatrix Cardiovascular Inc revealed on Tuesday that it has received US FDA 510(k) market clearance for the Cor PATCH for epicardial tissue support and repair in adult patients.

The company added that the Cor PATCH epicardial patch is the first epicardial cardiovascular medical device that is composed of US FDA approved first next generation CorMatrix ECM for the US cardiac surgery market.

According to the company, the Cor PATCH is used for the epicardial support and repair of atria and/or the right and left ventricular walls of the heart that have been thinned or damaged as a result of myocardial infarct.

In addition, the Cor PATCH is first in a series of products to address clinical challenges in the cardiovascular disease market, to include regenerative and innovative design solutions for congestive heart failure, and adult or paediatric cardiac valve patients, concluded the company.



Related Headlines